4072 results about "Heavy chain" patented technology

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.

The invention discloses an antibody for resisting HPV16 type E6 protein and E7 protein, a detection product and application of the antibody and the detection product, and relates to the technical field of monoclonal antibodies. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 E6 protein and E7 protein, and a detection product for detecting the HPV16 E6 / E7 antigen can be developed based on the antibody provided by the invention. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, rapidness and strong tolerance on the HPV16 E6 / E7 antigen, can be used for quality control in the production process of the recombinant human HPV16 E6 / E7 antigen, and can efficiently and accurately quantify the antigen content in a vaccine and monitor the quality of the vaccine.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 nano antibody, a recombinant nano antibody, a recombinant vector and application. The anti-IL-6 nano antibody disclosed by the invention comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a recombinant nano antibody containing the nano antibody, a recombinant vector and a detection agent, and applications of the nano antibody, the recombinant nano antibody, the recombinant vector and the detection agent in preparation of drugs for treating IL-6 related diseases. The nano antibody, the recombinant nano antibody and the recombinant vector provided by the invention can recognize and combine IL-6, and have a potential effect of treating IL-6-related diseases.

The invention belongs to the technical field of immunology, and particularly relates to a targeted IL-6 biological nano antibody and application thereof. The invention discloses a nano antibody for targeting IL-6, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a composition containing the nano antibody or the IL-6 binding molecule, and an application of the composition containing the nano antibody and the IL-6 binding molecule in preparation of drugs for treating IL-6 related diseases. The nano antibody, the BCMA binding molecule and the composition can recognize and bind IL-6, and have a potential effect of treating IL-6 related diseases.

The invention discloses a monoclonal antibody for distinguishing a hog cholera lapinized virus vaccine strain and a hog cholera lapinized virus epidemic strain and application of the monoclonal antibody, and belongs to the field of immune globulin. The E2 protein monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The invention also discloses an ELISA method for identifying and distinguishing hog cholera lapinized virus vaccine strains and epidemic strains by using the E2 protein monoclonal antibody. The monoclonal antibody disclosed by the invention has a specific reaction with the swine fever virus epidemic strain and does not react with the swine fever lapinized virus vaccine strain, and the swine fever lapinized virus vaccine strain and the epidemic strain can be accurately identified and distinguished by utilizing an ELISA competition method established by the monoclonal antibody. The monoclonal antibody provided by the invention can be used in the fields of CSFV immunization, serological diagnosis of wild viruses, immune effect evaluation, related experiments and the like, and provides antibody resources for effective detection and purification of CSFV.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 4F6 for HPV16 type E7 protein detection and application. The heavy chain variable region CDR sequences and the light chain variable region CDR sequences of the antibody are SEQ ID NO.1-3 and SEQ ID NO.4-6 respectively, and the antibody can be specifically combined with HPV16 type E7 protein without cross reaction. A double-antibody sandwich ELISA detection system constructed based on the antibody is combined with a biotin-avidin amplification technology, the sensitivity reaches 100 pg / mL, and the antibody is suitable for rapid detection of the HPV16 type E7 protein in a cervical exfoliated cell sample. The invention further provides the HPV16 type E7 recombinant protein which is obtained through prokaryotic expression and has immunocompetence, and the HPV16 type E7 recombinant protein is applied to antibody screening and detection. Compared with nucleic acid detection, the method has a lower false positive rate, can be used for early screening of cervical cancer and precancerous lesions, and has a good application prospect.

Provided herein are antibodies that specifically bind to MICA / B having a heavy chain, a light chain, a variable heavy chain domain (VH), a variable light chain domain (VL), and a complementarity determining region (CDR) disclosed herein, as well as methods and uses thereof.

This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

The present invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting HPV18 E7 protein and its application. This combination consists of monoclonal antibodies 5F8 and 6G6, wherein the heavy and light chain variable regions of 5F8 and 6G6, respectively, contain specific complementarity-determining region sequences (as shown in SEQ ID NOs. 1 to 12), conferring high specificity for HPV18 E7 protein. Verification using a double-antibody sandwich ELISA and a biotin-avidin amplification system demonstrated that this antibody combination specifically recognizes HPV18 E7 protein, exhibits no cross-reactivity with other high-risk HPV oncoproteins, and exhibits a detection sensitivity of 1 ng / mL. This combination can be used to construct detection systems such as ELISA kits and immunochromatographic test strips, suitable for rapid screening of HPV18 E7 protein in cervical exfoliated cell samples.

The invention discloses an anti-pestivirus broad-spectrum neutralizing monoclonal antibody and application thereof, and belongs to the field of immune globulin. The anti-pestivirus monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The monoclonal antibody provided by the invention can identify hog cholera virus and all known plague virus members (BVDV1, BVDV2, BDV, HoBiPeV, AydinPeV and OVPV) capable of infecting cattle and sheep at present, has good neutralizing ability, and can be prepared into a diagnostic product for plague virus antigen-antibody detection. The monoclonal antibody and a diagnostic product developed based on the monoclonal antibody can be used for serological diagnosis and immune effect evaluation of pestivirus, pestivirus pathogen detection of experimental serum products and the like, and have wide application prospects in the fields of clinical diagnosis and the like.

The invention discloses an anti-interleukin-6 antibody or a reagent and a kit for detecting interleukin-6, and relates to the field of antibodies. The anti-interleukin-6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin-6, and has good affinity or activity.

The invention discloses an anti-cortisol antibody or a cortisol detection reagent and kit, and relates to the field of antibodies. The anti-cortisol antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cortisol, and has good affinity or activity.

The invention relates to the technical field of a preparation method of a type A recombinant botulinum toxin, in particular to a type A botulinum toxin obtained by adopting a gene recombination technology, and the amino acid sequence of the type A botulinum toxin is consistent with the sequence of the type A botulinum toxin prepared by extracting and purifying a wild strain Clostridium botulinum. According to the technical scheme, the single-chain protein of the botulinum toxin A sequentially comprises a botulinum toxin A light chain or a modified botulinum toxin A light chain, a connecting region and a botulinum toxin A heavy chain. According to the scheme, the high-quality recombinant botulinum toxin A is obtained after the single-chain protein is subjected to fermentation, crude purification, enzyme digestion and fine purification. According to the technical scheme, the problems of complex process, long period, high safety risk and the like in the existing process for preparing the botulinum toxin A from the wild bacterial strain clostridium botulinum can be solved, and meanwhile, the problem that the amino acid sequence consistent with that of the botulinum toxin A prepared from the wild bacterial strain clostridium botulinum cannot be obtained through the existing gene recombination technology is solved.

The invention provides an anti-human CD117 monoclonal antibody and an application thereof. The anti-human CD117 monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and the amino acid sequence of the light chain complementary determining regions is as shown in SEQ ID NO: 6. The amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with the existing known anti-human CD117 monoclonal antibody, the antibody disclosed by the invention shows better cellular level biology, and is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The invention discloses an anti-human hepatitis B e antigen monoclonal antibody and application thereof, and relates to the technical field of hepatitis B detection. In a heavy chain variable region of the monoclonal antibody, an amino acid sequence of a complementarity determining region CDR1-3 is as shown in SEQ ID NO.1-3 or has at least 95% of homology with the sequence as shown in SEQ ID NO.1-3; in the light chain variable region, amino acid sequences of complementary determining regions CDR1 and CDR3 are shown as SEQ ID NO.4 and SEQ ID NO.5 or have at least 95% of homology with the sequences shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of a complementary determining region CDR2 is FAS. The monoclonal antibody provided by the invention can well recognize a natural hepatitis B e antigen, and the titer of a supernatant cultured by a B cell can reach 1: 10000, so that the monoclonal antibody can be completely applied to detection research of the human hepatitis B e antigen. The chemiluminescence reagent prepared by using the monoclonal antibody has the advantages of high specificity, strong anti-interference capability, high detection sensitivity, good stability and the like, almost has no leak detection, and can replace an imported reagent.

The invention relates to the technical field of biomedicine, in particular to an anti-influenza A virus NP protein antibody pair and application thereof. The antibody pair comprises two monoclonal antibodies; the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; one monoclonal antibody in the monoclonal antibody pair is named as a 10G10 antibody, and the other monoclonal antibody is named as a 11F8 antibody. The invention also discloses a nucleic acid molecule for coding the monoclonal antibody and a hybridoma cell strain for secreting the monoclonal antibody. In addition, the invention also discloses a kit for detecting influenza virus protein, which comprises the monoclonal antibody pair, the 10G10 antibody is used as a capture antibody, and the 11F8 antibody is used as a labeled antibody. The antibody for resisting the influenza A virus NP protein provided by the invention has relatively good specificity on the influenza virus protein.

The invention discloses monoclonal antibodies NP5 and NP8 for resisting influenza A virus NP protein and application of the monoclonal antibodies NP5 and NP8, and belongs to the technical field of monoclonal antibodies. According to the invention, 19 influenza A virus NP protein monoclonal antibodies are prepared, and the monoclonal antibodies NP5 and NP8 are obtained by screening through ELISA (enzyme-linked immuno sorbent assay) detection and sequencing analysis. The NP5 comprises a light chain CDR2 of which the amino acid sequence is RTS, light chains CDR1 and CDR3 of which the amino acid sequences are shown as SEQ ID NO.3-4, and heavy chains CDR1-3 of which the amino acid sequences are shown as SEQ ID NO.7-9; the NP8 comprises a light chain CDR2 of which the amino acid sequence is LVS, light chains CDR1 and CDR3 of which the amino acid sequences are as shown in SEQ ID NO.12 to SEQ ID NO.13, and heavy chains CDR1-3 of which the amino acid sequences are as shown in SEQ ID NO.16 to SEQ ID NO.18. The invention lays a foundation for preparing an influenza A virus detection kit.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey C-reactive protein monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named CRP-13, CRP-13 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequences are shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequences are shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey C-reactive protein with high specificity. The above monoclonal antibody can be used to screen a paired monoclonal antibody, and a monkey C-reactive protein enzyme-linked immunosorbent assay kit is obtained based on the combination of the monoclonal antibodies, which can detect the content of monkey C-reactive protein in monkey serum, plasma or tissue fluid.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat FGF23 protein and application. The invention provides a monoclonal antibody combination with high specificity and strong sensitivity aiming at cat FGF23 protein. The antibody combination comprises monoclonal antibodies 5A2 and 3A1. By designing and optimizing complementary determining region (CDR) sequences of heavy chain and light chain variable regions, CDR amino acid sequences are respectively shown as SEQ ID NO.1 to SEQ ID NO.12, and the antibody combination has excellent binding activity and detection specificity. A double-antibody sandwich ELISA detection method constructed on the basis of the antibody combination has relatively high sensitivity, and the accuracy of a detection result is remarkably improved.

The invention belongs to the field of antibodies, and particularly relates to an anti-NMP22 monoclonal antibody as well as a preparation method and application thereof. The invention provides CDR sequences of a heavy chain variable region and a light chain variable region of an anti-NMP22 antibody, the antibody can specifically recognize nuclear matrix protein 22 (NMP22), has high affinity and high specificity to the protein, can be applied to diagnosis of diseases related to abnormal urine nuclear matrix protein 22 level, and especially can be applied to clinical diagnosis of bladder cancer.

The invention belongs to the field of biological detection, and discloses a kit for detecting cervical cancer and application of the kit. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the heavy chain amino acid sequence of the monoclonal antibody CPT1A-1 of the anti-CPT1A protein in the capture antibody is as shown in SEQ ID NO. 1, and the light chain amino acid sequence is as shown in SEQ ID NO. 2; the heavy chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody CPT1A-2 of the anti-CPT1A protein in the HRP labeled antibody is as shown in SEQ ID NO.4. The kit for diagnosis of cervical cancer provided by the invention has strong specificity, can specifically detect the content of CPT1A protein in serum, has good stability, and has good application prospects.

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody, an IgM antibody and a method. The invention provides an IgG (immunoglobulin G) antibody specifically bound with coxsackie virus, which is characterized in that amino acid sequences of complementary determining regions CDRH1-CDRH3 of a heavy chain variable region of the IgG antibody are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; the amino acid sequences of the complementary determining regions CDRL1-CDRL3 of the light chain variable region are respectively as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The IgG antibody provided by the invention not only has good specificity and can specifically recognize the coxsackie virus, but also has high sensitivity and stability.

The invention belongs to the field of monoclonal antibodies, and particularly relates to a mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody and application, a CDR region of a heavy chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.1-3, and a CDR region of a light chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.4-6; the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody can be obtained by being secreted by a hybridoma cell strain PFM-1B7C12A1B2 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: C2024234. The mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of IgM in a pelteobagrus fulvidraco secretion form, and can be used for flow cytometry identification of pelteobagrus fulvidraco IgM + B cells. The monoclonal antibody is good in specificity, high in sensitivity and strong in affinity, can be used for structural analysis, immune response level detection and the like of pelteobagrus fulvidraco IgM, and lays a foundation for in-depth study of a pelteobagrus fulvidraco immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.

The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit, and belongs to the technical field of antibodies and immunodetection, the anti-p-Tau217 antibody comprises a heavy chain variable region and a light chain variable region, a coding gene of the heavy chain variable region comprises a nucleotide sequence shown in SEQ ID NO.1, and a coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQ ID NO.2. The coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQIDNO.3, the heavy chain variable region comprises an amino acid sequence shown in SEQIDNO.2, and the light chain variable region comprises an amino acid sequence shown in SEQIDNO.3. The invention also discloses a preparation method. The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit. The successful expression of the monoclonal anti-p-Tau217 antibody with high affinity is realized, and the monoclonal anti-p-Tau217 antibody is used for detecting the Alzheimer's disease.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein and application of the antibody, and relates to the technical field of biological medicine. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 and / or HPV18 type E2 protein. Based on the antibody provided by the invention, a reagent, a kit, a test strip, an antibody chip, an antibody probe or a detector for detecting the HPV16 and / or HPV18 type E2 antigen can be developed. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity / specificity, high precision, high accuracy, fast detection and strong tolerance, and can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigens.

The invention relates to the technical field of biological detection, in particular to a monoclonal antibody combination for HPV18 type E6 protein detection and application. The provided combination is composed of 5G3 and 2C7, and the amino acid sequences of complementary determining regions of variable regions of a heavy chain and a light chain of the combination are clear and are respectively shown as SEQ ID NO.1-12. The antibody combination has high specificity and sensitivity, the lowest detection limit can reach 100 pg / ml, and cross reaction with other HPV subtypes is avoided. According to a double-antibody sandwich ELISA and biotin-avidin amplification detection system constructed based on the combination, the signal intensity and the detection accuracy are remarkably improved, and the combination is suitable for rapid detection of the HPV18 type E6 protein in a cervical exfoliated cell sample and has application value in early diagnosis of cervical cancer, risk stratification, vaccine research and development and curative effect evaluation.

The invention discloses an anti-TL1A antibody and a preparation method and application thereof in the technical field of biological medicine. The anti-TL1A antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The antibody provided by the invention has relatively high affinity and better biological activity characterization, and the epitope is different from that of a traditional anti-TL1A antibody.

The invention discloses preparation of an antibody capable of detecting multi-subtype KPC and application of a kit of the antibody, and belongs to the field of biological medicine. According to the kit for detecting the common subtypes of KPC and the application of the kit, the mouse antibodies are prepared through immunization of conserved antigen epitopes of all the subtypes of KPC, in-vitro screening and pairing are carried out in multiple modes, then an antibody pair which is good in specificity and high in affinity and can be combined with multiple subtypes is obtained, the titer of the two antibodies can reach one million or above, and the kit is high in specificity, good in affinity and capable of being used for detecting the common subtypes of KPC. Amino acid sequences of a heavy chain variable region and a light chain variable region are obtained through sequencing, and rapid and stable expression can be realized after recombination. The product for detecting the carbapenem KPC is developed on the basis of an immunochromatography platform, and the kit has the advantages of high sensitivity, good specificity, good stability, capability of covering most epidemic KPC subtypes and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.